Dr Reddy's Lab inches up after launching Paricalcitol injection

Dr Reddy's Laboratories rose 0.96% to Rs 3,186.95 at 9:25 IST on BSE after the company launched Paricalcitol injection, USP in the United States.

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the S&P BSE Sensex was down 50.36 points or 0.18% at 28,584.14

On BSE, so far 1,437 shares were traded in the counter as against average daily volume of 39,235 shares in the past one quarter. The stock hit a high of Rs 3,190 and a low of Rs 3,165 so far during the day. The stock had hit a a record high of Rs 4,382.95 on 20 October 2015. The stock had hit a 52-week low of Rs 2,750 on 21 January 2016.

 

The large-cap company has equity capital of Rs 85.39 crore. Face value per share is Rs 5.

Dr Reddy's Laboratories said it has launched Paricalcitol injection, USP, a therapeutic equivalent generic version of Zemplar (Paricalcitol) injection in the United States market approved by the US Food & Drug Administration (USFDA). The Zemplar brand and generic had US sales of approximately $22.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health. Dr. Reddy's Paricalcitol Injection is available in 2 mcg, 5 mcg, and 10 mcg, and is the first ANDA product launched in the US market.

Dr Reddy's Laboratories' consolidated net profit fell 76.3% to Rs 153.50 crore on 14.1% decline in total income to Rs 3289.50 crore in Q1 June 2016 over Q1 June 2015.

Dr Reddy's Laboratories is an integrated global pharmaceutical company. It offers a portfolio of products and services including active pharmaceutical ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Powered by Capital Market - Live News